Compare GraniteShares 2x Long COIN Daily ETF (CONL) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GraniteShares 2x Long COIN Daily ETF vs Zimmer Biomet Holdings Inc — how do they compare? GraniteShares 2x Long COIN Daily ETF trades at $5.09 (market cap $510.01M), while Zimmer Biomet Holdings Inc trades at $89.66 (market cap $16.95B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 33.2× GraniteShares 2x Long COIN Daily ETF's market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while GraniteShares 2x Long COIN Daily ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold GraniteShares 2x Long COIN Daily ETF for 15 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| CONL | ZBH | |
|---|---|---|
Market Cap | $510.01M | $16.95B |
Volume | 21,041,836 | 2,505,240 |
Sector | Leveraged / Inverse | Health |
52-Week High | $48.58 | $103.98 |
52-Week Low | $3.93 | $79.58 |
Typical Hold Time | 15 Days | 89 Days |
Enterprise Value | — | $24.02B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CONL (GraniteShares 2x Long COIN Daily ETF) trades at $4.91, down 6.12% with bearish technical signals from moving averages. The ETF tracks Coinbase stock with 2x daily leverage, amplifying volatility. Recent news highlights significant price gaps and performance swings, with one article noting an 85% decline when Coinbase fell 50%. Technical indicators show oversold conditions with RSI readings below 30, suggesting potential near-term bounce.
Outlook remains highly speculative due to leveraged structure and dependency on Coinbase performance. Investment opportunity exists for tactical traders betting on Coinbase recovery, but risks include amplified losses, daily rebalancing decay, and crypto market volatility. Conservative investors should avoid due to extreme risk profile.
Zimmer Biomet (ZBH) trades at $88.49, down 1.33% today, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $2.07 surpassing the $2.01 estimate. Revenue growth is steady, reaching $8.23B in 2025, though net income margin has moderated to 9.48%. A quarterly dividend of $0.24 was declared, payable in October 2026. Analyst consensus price target is $103.11, implying potential upside from current levels.
The outlook is mixed: solid fundamentals and earnings momentum support long-term value, but technical weakness and elevated debt levels pose near-term risks. Investment appeal hinges on execution of commercial transformation and robotics adoption offsetting competitive pressures. Key risks include margin compression and macroeconomic sensitivity affecting procedure volumes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GraniteShares 2x Long COIN Daily ETF
CONL is a leveraged ETF that seeks to provide two times (2x) the daily performance of Coinbase Global (COIN) stock. It is designed for investors seeking magnified short-term exposure to the price movements of Coinbase.
Read more on CONL →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
